Phase 0.5? FDA Guidance Allows Pre-Clinical Micro-Dose Studies In Human Subjects
This article was originally published in The Pink Sheet Daily
Executive Summary
Aimed at academic researchers, FDA's final guidance permits study of the mechanism of action of new agents at low doses.